Enterprise Therapeutics

Enterprise Therapeutics is a biopharmaceutical company focused on discovering and developing novel therapies for respiratory diseases. Their lead program, ETD001, is a first-in-class ENaC blocker targeting cystic fibrosis, aiming to improve lung function and reduce morbidity. The company's pipeline includes other disease-modifying therapies targeting mucus congestion in conditions like COPD and severe asthma.

Buy Funded Startups lists

Funding Round: Series B

Funding Amount: $33.1M

Date: 30-Jan-2024

Investors: Panakes Partners, Versant Ventures, Novartis Venture Fund, Forbion, Epidarex Capital, IP Group

Markets: Biopharmaceuticals, Respiratory Disease Therapeutics, Health Care, Health Diagnostics, Therapeutics, Biotechnology, Drug Discovery

HQ: Brighton, East Sussex, United Kingdom

Founded: 2014

Website: https://www.enterprisetherapeutics.com/

LinkedIn: https://uk.linkedin.com/company/enterprise-therapeutics

Twitter: https://twitter.com/enterprisethera

Instagram: